help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on August 23, 2007
Endocrinology, doi:10.1210/en.2007-0520
A more recent version of this article appeared on November 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
148/11/5323    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caverzasio, J.
Right arrow Articles by Manen, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caverzasio, J.
Right arrow Articles by Manen, D.

Submitted on April 20, 2007
Accepted on August 10, 2007

Essential role of Wnt3a-mediated activation of MAP kinase p38 for the stimulation of alkaline phosphatase activity and matrix mineralization in C3H10T1/2 mesenchymal cells

Joseph Caverzasio* and Danielle Manen

Service of Bone Diseases, Department of Rehabilitation and Geriatrics, University Hospital of Geneva, CH-1211 Geneva 14, Switzerland

* To whom correspondence should be addressed. E-mail: Joseph.Caverzasio{at}medecine.unige.ch.

Signaling pathways involved in the development of osteoprogenitors induced by Wnts remain poorly understood. In this study, we investigated the role of MAP kinases in the development of mesenchymal cells into osteoprogenitors. In C3H10T1/2 mesenchymal cells, Wnt3a induced a rapid and transient activation of MAP kinases p38 and ERK. DKK1, a selective antagonist of Wnt proteins binding to LRP5/6 did not influence activation of p38 and ERK induced by Wnt3a. A MEK1,2 inhibitor blocked whereas a p38 inhibitor had no effect on Wnt3a-induced cell proliferation. In contrast, both inhibitors significantly reduced ALP stimulation with a more pronounced effect of the p38 inhibitor. The p38 inhibitor also blunted nodules mineralization induced by Wnt3a. Associated with these effects, {beta}-catenin transcriptional activity, assessed with the TOPflash system, was dose-dependently decreased by the p38 but not by the ERK inhibitor. Both, the reduced ALP stimulation and blunting of {beta}-catenin transcriptional activity were mimicked by expression of dnp38 and dnMkk3/6. Inhibition of {beta}-catenin transcriptional activity by the p38 inhibitor as well as by dnp38 and dnMKK3/6 molecules were not associated with changes in cytosolic and nuclear {beta}-catenin levels induced by Wnt3a.

In conclusion, Wnt3a activates ERK and p38 in mesenchymal C3H10T1/2 cells by a LRP5/6-independent mechanism. Activation of p38 regulates alkaline phosphatase activity and nodules mineralization induced by Wnt3a probably by interacting with {beta}-catenin transcriptional activity. These observations suggest that MAP kinases ERK and p38 are probably essential pathways activated by Wnt proteins for the development of mesenchymal cells into osteoprogenitors.


Key words: Wnt signaling • p38 MAP kinase • alkaline phosphatase • mineralization







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society